KR102793446B1 - Btk 억제제로서의 피롤로피리미딘 화합물 및 이의 용도 - Google Patents

Btk 억제제로서의 피롤로피리미딘 화합물 및 이의 용도 Download PDF

Info

Publication number
KR102793446B1
KR102793446B1 KR1020227018702A KR20227018702A KR102793446B1 KR 102793446 B1 KR102793446 B1 KR 102793446B1 KR 1020227018702 A KR1020227018702 A KR 1020227018702A KR 20227018702 A KR20227018702 A KR 20227018702A KR 102793446 B1 KR102793446 B1 KR 102793446B1
Authority
KR
South Korea
Prior art keywords
compound
equiv
added
mixture
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227018702A
Other languages
English (en)
Korean (ko)
Other versions
KR20220097455A (ko
Inventor
양 장
웬타오 우
카이준 겅
치우 리
지안 리
슈후이 첸
Original Assignee
제지앙 롱샴 바이오-테크 파르마. 씨오., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제지앙 롱샴 바이오-테크 파르마. 씨오., 엘티디. filed Critical 제지앙 롱샴 바이오-테크 파르마. 씨오., 엘티디.
Publication of KR20220097455A publication Critical patent/KR20220097455A/ko
Application granted granted Critical
Publication of KR102793446B1 publication Critical patent/KR102793446B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227018702A 2019-11-13 2020-11-13 Btk 억제제로서의 피롤로피리미딘 화합물 및 이의 용도 Active KR102793446B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201911109773.2 2019-11-13
CN201911109773 2019-11-13
CN201911288492 2019-12-13
CN201911288492.8 2019-12-13
CN202010096582.3 2020-02-17
CN202010096582 2020-02-17
CN202010711270.9 2020-07-22
CN202010711270 2020-07-22
PCT/CN2020/128597 WO2021093839A1 (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用

Publications (2)

Publication Number Publication Date
KR20220097455A KR20220097455A (ko) 2022-07-07
KR102793446B1 true KR102793446B1 (ko) 2025-04-09

Family

ID=75912541

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018702A Active KR102793446B1 (ko) 2019-11-13 2020-11-13 Btk 억제제로서의 피롤로피리미딘 화합물 및 이의 용도

Country Status (6)

Country Link
US (1) US12378253B2 (cg-RX-API-DMAC7.html)
EP (1) EP4059935A4 (cg-RX-API-DMAC7.html)
JP (1) JP7473642B2 (cg-RX-API-DMAC7.html)
KR (1) KR102793446B1 (cg-RX-API-DMAC7.html)
CN (2) CN114728974B (cg-RX-API-DMAC7.html)
WO (1) WO2021093839A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234558A4 (en) * 2020-12-07 2024-10-23 Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. PYRROLOPYRIDINE COMPOUND AND APPLICATION THEREOF
CN114761410B (zh) * 2021-04-06 2023-08-25 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
JP7645573B2 (ja) * 2021-05-12 2025-03-14 ジャージアン・ロングチャーム・バイオ-テック・ファーマ・カンパニー・リミテッド ピロロピリミジン類化合物の結晶形およびその調製方法
CN117500806A (zh) * 2021-05-28 2024-02-02 默沙东有限责任公司 Btk抑制剂及其中间体的合成
EP4448523A1 (en) 2021-12-14 2024-10-23 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors
CN115894500B (zh) * 2022-11-02 2024-05-28 中国药科大学 一种作为btk激酶抑制剂的化合物及其制备方法与用途
CN118702697A (zh) * 2023-03-18 2024-09-27 山东新时代药业有限公司 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
CN116375715B (zh) * 2023-04-06 2025-04-04 中国药科大学 一种作为非共价btk激酶抑制剂的化合物及其生物用途
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
HRP20170311T1 (hr) * 2012-08-06 2017-04-21 Acea Biosciences Inc. Novi spojevi pirolopirimidina kao inhibitori protein kinaza
EP3042903B1 (en) * 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
AU2015417922B2 (en) 2015-12-23 2018-12-20 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
AU2017315343A1 (en) 2016-08-24 2019-02-28 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof

Also Published As

Publication number Publication date
CN114728974A (zh) 2022-07-08
CN114728974B (zh) 2023-09-19
JP2023506691A (ja) 2023-02-20
EP4059935A4 (en) 2024-02-28
KR20220097455A (ko) 2022-07-07
US20230357248A1 (en) 2023-11-09
CN117551103A (zh) 2024-02-13
WO2021093839A1 (zh) 2021-05-20
US12378253B2 (en) 2025-08-05
EP4059935A1 (en) 2022-09-21
JP7473642B2 (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
CN114728974B (zh) 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
CA3158749C (en) PYRROLOTRIAZINE COMPOUNDS ACTING AS MNK INHIBITORS
JP7374532B2 (ja) 選択性の高いros1阻害剤としての化合物、及びその使用
CN113993860B (zh) 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物
US20250051330A1 (en) Heterocyclic compound having anti-tumor activity and use thereof
CA2881275C (en) Pyrrolopyrimidine compounds as inhibitors of protein kinases
JP2011515370A (ja) 4−アミノ−5−フルオロ−3−[5−(4−メチルピペラジン−1−イル)−1h−ベンズイミダゾール−2−イル]キノリン−2(1h)−オン乳酸塩の結晶形態及び2つの溶媒和物形態
JP7574450B2 (ja) アミノピリジン系化合物及びその使用
CN114008046A (zh) 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
US20210386737A1 (en) Dihydroimidazopyrazinone compound, composition including same, and use thereof
CN115210226B (zh) 喹啉类化合物
US8343977B2 (en) Substituted triazolo-pyrimidine compounds
CN116710460A (zh) 联苯衍生物及其应用
CN116438175B (zh) 苯并脲环衍生物及其制备方法和应用
AU2024289347A1 (en) Nmt inhibitor, and preparation method therefor and use thereof
JP7296017B2 (ja) ベンゾスルタムを含む化合物
TW202330534A (zh) 吡唑並環化合物及其應用
HK40080199A (en) Pyrrolopyrimidine compound as btk inhibitor and use thereof
CN113286594B (zh) 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
CN118139865A (zh) 吡咯并吡唑螺环化合物
CN116490504A (zh) 吡咯并吡啶类化合物及其应用
CN116529249A (zh) 吡啶并嘧啶酮类化合物
EA046344B1 (ru) Соединение в качестве высокоселективного ингибитора ros1 и его применение
HK40071305A (en) Deuterated thienopyridine compound

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20220602

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220602

Comment text: Request for Examination of Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20221013

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240812

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250317

PG1601 Publication of registration